GlassScriptPhysician profile
Sean T Lynch
NPI 1366672040
$853.12
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $440 · 2023: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $195.37 | 2022 | |
| Novo Nordisk INC | $91.53 | 2022 | |
| Lilly USA, LLC | $81.35 | 2021-2023 | Mounjaro |
| Phadia US INC. | $70.44 | 2021-2023 | Immunocap |
| Amgen INC. | $65.86 | 2022-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $49.06 | 2022 | |
| Exact Sciences Corporation | $47.34 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $46.94 | 2022-2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $36.60 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.90 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $24.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.33 | 2022 | |
| Cvrx, INC. | $21.72 | 2023 | Barostim Neo System |
| Pfizer INC. | $18.96 | 2021 | |
| Astellas Pharma US INC | $18.79 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.47 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.